Medical device company Mitralign closed on $35 million in a Series D financing led by Forbion Capital Partners, with contributions from a handful of other investors. Mitralign is developing a cardiac device for percutaneous mitral valve repair and has raised $77 million in venture funding to date. The device is for treating Functional Mitral Regurgitation, or mitral insufficiency, the most common form of valvular heart disease.
